In inpatient glycemic management, the challenge is not simply lowering glucose. It is doing so without causing harm. That is why new EndoTool IV data being presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 matter: across 19 hospitals, severe hypoglycemia fell 98% versus paper protocols, while severe hyperglycemia remained low at 0.17%.

The poster reports a three-year retrospective analysis from January 2023 through December 2025, covering 17,838 patients and 362,901 blood glucose values. Severe hypoglycemia incidence dropped to 0.005% compared with 0.23% under historical paper protocols. In 4,804 patients treated through DKA-specific protocols, severe hypoglycemia incidence was only 0.007%. Just as important, the analysis found that 2,213 potential episodes of hypoglycemia were avoided because EndoTool IV recommended prophylactic carbohydrates before blood glucose dropped below 70 mg/dL.

One of the most compelling parts of the poster is the renal story. Patients with severe renal impairment are often among the most difficult and highest-risk populations in inpatient insulin management. In this analysis, patients with eGFR <15 had a severe hypoglycemia incidence of 0.007%, compared with 0.005% in patients with eGFR >60. That finding aligns closely with EndoTool’s approved differentiation around patient-specific dosing, residual insulin calculation, and support for safer dosing in patients with reduced renal function.

This is where the “so what” becomes clear. Hospitals are facing more pressure to improve glycemic safety, and severe hypoglycemia and hyperglycemia are more visible quality concerns than they were even a few years ago. A tool that can help reduce patient harm, support more standardized insulin dosing, and give teams more confidence in complex cases is not just clinically useful – it is strategically relevant.

The EndoTool message has long been that inpatient insulin management should be safer, simpler, and more standardized. EndoTool is patient-specific, capable of adjusting for kidney function and steroid use, and able to recommend proactive carbohydrate interventions when hypoglycemia appears imminent. This can lead to reduced cognitive burden for clinicians, more consistent protocols, and better support for frontline teams. This new poster gives that story fresh, real-world, health-system-scale evidence.

The bigger takeaway is this: hospitals should not have to choose between reducing hypoglycemia and maintaining glycemic control. These data suggest that patient-specific insulin dosing can help achieve both. And in today’s environment, that is a story worth paying attention to.

Download poster

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool’s ability to use available patient information within the hospital’s electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.

The Glooko team is thrilled to head to Las Vegas from April 22 to 24 for the 2026 American Association of Clinical Endocrinology (AACE) Annual Meeting, the premier event for endocrinology experts that brings together clinicians, researchers, and innovators to share cutting-edge science, clinical insights, and innovations shaping the future of endocrine care.

Our poster presentation, “Virtual Elimination of Severe Hypoglycemia Utilizing a Computerized Insulin Dosing Algorithm for Intravenous Insulin Infusions,” will take place at AACE on Thursday, April 23 from 11:10–11:25 a.m. PDT at Poster Station 4, Learning Zone, Caesars Forum. Paul Chidester, MD, FACP, Medical Director for EndoTool at Glooko and Joseph Aloi, MD, FACE, Section Chief, Endocrinology and Metabolism at Advocate Health Wake Forest Baptist Hospital, will share outcomes from Advocate Health’s use of the EndoTool Glucose Management System, developed by Monarch Medical Technologies, a Glooko Company, for inpatient glycemic care across its 19-hospital health system.

Poster Presentation

• Virtual Elimination of Severe Hypoglycemia Utilizing a Computerized Insulin Dosing Algorithm for Intravenous Insulin Infusions
• Authors: Joseph Aloi, MD, FACE, Advocate Health Wake Forest Baptist Hospital; Paul Chidester, MD, FACP, Glooko
• Conference: American Association of Clinical Endocrinology (AACE) 2026 Annual Meeting

About EndoTool

EndoTool is the leading FDA-cleared, patient-specific inpatient insulin-dosing software trusted by 8 of the top 10 U.S. health systems to support safer, more consistent glycemic management. The solution’s unique algorithm models each patient’s clinical characteristics and response to insulin to provide optimal dosing recommendations, and reduce the risk of severe hypoglycemia to virtually zero.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool’s ability to use available patient information within the hospital’s electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.

Managing diabetes shouldn’t feel so time-intensive for healthcare providers.

The Glooko outpatient diabetes management platform benefits endocrinologists, nurses, diabetes educators, primary care providers, dietitians, and other clinicians at hospitals and health systems by unifying data from more than 200 diabetes and health monitoring devices and apps into a single, secure, EHR-integrated solution. By streamlining workflows and advancing remote collaboration with patients, Glooko frees up care teams to focus on what matters most: engaging with patients with diabetes and improving their health outcomes.

The Six Reasons Glooko is the Choice for Outpatient Diabetes Management by Hospitals and Health Systems

1. Integration with Leading EHRs to Streamline Workflows

Glooko’s outpatient digital health solution seamlessly integrates with leading EHR systems, including Epic, Oracle Health, MEDITECH, Greenway Health, eClinicalWorks, NextGen, and Athenahealth, via SMART on FHIR to securely centralize diabetes and related health data in one place, eliminating the need to switch platforms and find login credentials. Designed to streamline clinical workflows and save time, its EHR integrations help healthcare providers reduce burnout and work more efficiently using a single interface that has a complete view of patient health data.

2. Extensive Customer Support Offerings to Ensure Success

Glooko offers healthcare providers dedicated customer success managers, U.S.-based support, and expert-led implementation of our diabetes connected care platform. Backed by an extensive help center, rapid response times, and comprehensive training resources, we ensure care teams at hospitals and health systems have the support they need to provide the highest quality care to people living with diabetes.

3. Most Secure Diabetes Management Platform to Advance Patient Safety

As the only diabetes management company with multiple industry-leading certifications from leading global security and privacy organizations, Glooko sets the standard for data privacy. We protect sensitive information through hundreds of robust controls and annual third-party audits. By prioritizing security, we help secure sensitive data, ensure patient safety, and reduce breach risks, while providing uninterrupted and protected access for both patients and healthcare providers.

4. Evidence-based Care to Deliver Sustainable and Measurable Health Outcomes

With our evidence-based diabetes management platform, people living with diabetes experience more stable blood glucose levels, increased time in range, better overall glycemic control, and a stronger sense of empowerment in managing their own health using the Glooko Mobile App. Multiple studies have been conducted where immediate and sustained improvements across glycemic outcomes were observed following remote patient monitoring powered by Glooko. By improving patient health, Glooko unlocks cost savings and elevates performance across value-based care metrics.

5. Largest Device Ecosystem to Integrate Health Data Seamlessly

With the largest device ecosystem, the device-agnostic Glooko solution streamlines diabetes management for care teams and people with diabetes. The innovative platform seamlessly integrates with more than 200 diabetes and health monitoring devices and apps, including CGMs, BGMs, insulin pumps and pens, and fitness trackers, to consolidate fragmented data into a single, actionable view. By integrating patient data, Glooko enables more informed, personalized, data-driven treatment by healthcare providers.

6. Population-Level Insights to Empower Diabetes Care Teams

Designed for busy care teams, Glooko’s clinic dashboard simplifies the complexity of managing large diabetes populations through a user-friendly, data-driven interface. By leveraging TIDE metrics and the CGM Patient Risk Stratification feature, healthcare providers can prioritize care by focusing their time and interventions on the patients who need them most. The tool, available in select countries, optimizes diabetes population health management by providing quick, actionable insights into patient trends and key clinic metrics.

Experience our Outpatient Diabetes Connected Care Solution

Schedule a demo of Glooko, our comprehensive diabetes management platform trusted by leading healthcare organizations, that enables clinical workflow optimization and improved health outcomes in the outpatient setting.

Inpatient glycemic safety is no longer just a clinical goal — it’s now a visible, system-level performance measure. With CMS requiring eCQM reporting for severe hypoglycemia and hyperglycemia as part of the Inpatient Quality Reporting (IQR) program, variations in workflows and insulin management are becoming consequential.

Moderated by Becker’s Healthcare, Glooko’s Paul Chidester, MD, FACP, NYC Health and Hospitals Lincoln’s Lewis Marshall Jr., MD, Hackensack Meridian Jersey Shore University Medical Center’s Harpreet Pall, MD, and Temple University Health System’s Benjamin Slovism, MD, share strategies they are implementing to support frontline clinicians with inpatient glycemic safety, standardize clinical workflows, and align glycemic management to meet these new CMS reporting mandates.

Key Takeaways

• Ways CMS reporting is changing inpatient glycemic safety expectations
• How operational and workflow variability can undermine performance
• Practical strategies for improving insulin management consistency without limiting clinical judgment
• How to measure, monitor, and sustain glycemic safety at scale

Watch the Webinar

Catch a Recap

Read a recap of the Glooko-hosted Becker’s Healthcare webinar to learn why glycemic safety efforts often fall short and how leaders are building the infrastructure and standardization needed to close those gaps.

Is your hospital ready to close CMS glycemic safety gaps?

Visit Glooko’s CMS Glycemic Safety Readiness Hub to take a five-minutes assessment that evaluates your hospital’s alignment with the CMS mandates and identifies priority areas during the active reporting period.

MKT-0558

This blog post features contributions from Glooko’s clinical team., including Amanda Edwards, BSN, RN, Amanda Heger, MSN, RN, AMB-BC, Christine Emery, BSN, RN, CCRN, Paul Chidister, MD, FACP, and Marc Clements, MD, PhD

As clinicians and health system leaders, you understand the critical nexus of diabetes and cardiovascular risk — a dual-threat that often dictates patient morbidity and mortality.

Both the American Heart Association (AHA) and the American Diabetes Association (ADA) identify diabetes as a powerful, controllable risk factor, noting that adults with diabetes are two to four times more likely to die from or develop these conditions ¹. Uncontrolled blood sugar is a major risk factor, making this link impossible to ignore, especially when cardiovascular disease causes roughly 65% to 75% of all-cause mortality in people with type 2 diabetes ².

Our digital health solutions, the EndoTool Glucose Management System, developed by Monarch Medical Technologies, a Glooko Company, and the Glooko diabetes management platform, are designed to support this complex relationship, providing a clear and efficient pathway to monitoring diabetes data and potentially protecting your patients‘ hearts.

EndoTool: Ensuring Inpatient Glycemic Stability and Supporting Cardiovascular Health

For critically ill patients recovering from acute cardiac events (myocardial infarction, heart failure, and post-surgery), safe, precise, and stable inpatient glucose management is crucial for minimizing complications, accelerating recovery, and ensuring discharge readiness. The dynamic ICU and cardiac step-down environments require a highly precise, algorithmic solution aligned with critical care protocols, such as those from the Institute of Critical Care Medicine (ICCM)⁶.

When patients recovering from acute cardiac events present with co-morbidities like acute kidney injury (AKI), standard insulin protocols prove insufficient to safely support altered renal function as this drastically impacts insulin clearance. EndoTool is engineered to navigate this metabolic complexity through the use of 11 patient-specific proprietary factors. These factors allow the system to create a truly individualized insulin management profile that accounts for:

• Renal Function: Adjusting for altered insulin clearance in AKI.
• Insulin Sensitivity and Resistance: Recognizing the significant variability in patient response.
• Glycemic Trajectory: Assessing the rate and direction of glucose change to proactively prevent excursions.

The Science of Control: EREI & Tight Algorithms for Unmatched Safety

EndoTool’s Estimated Residual Extracellular Insulin (EREI) Calculation is a cornerstone of its safety and effectiveness. EREI accurately quantifies „insulin on board,“ preventing dose compounding, a common cause of hypoglycemia in traditional protocols. This sophisticated estimation ensures precise, effective, and critically safe patient-specific dosing.

Preventing Hypoglycemia Before It Starts

Hypoglycemia is not just a complication; it is an independent risk factor for adverse cardiovascular events, including arrhythmias and increased mortality³,⁵. EndoTool’s design could help actively mitigate this risk factor:

• Engineered to Reduce Dual-Risk: EndoTool’s tight control algorithms are specifically engineered to help minimize both severe hyper- and hypoglycemia.
• Proof of Safety: Its algorithms achieved aggressive glucose targets with an unmatched safety profile: severe hypoglycemia (BG < 40 mg/dL) occurred in only 0.13% of all blood glucose readings in an ICU study ⁴.
• Proactive Carbohydrate Recommendations: When a rapid glucose decline signals impending hypoglycemia, the system not only holds the next insulin dose but also actively recommends supplemental carbohydrate intake. This proactive intervention stabilizes glucose before it reaches a dangerous threshold.

Case Study Snapshot: Atrium Health Wake Forest Baptist

Effective, stable inpatient glucose control is crucial for successful patient recovery and transition to outpatient care, supporting long-term glycemic targets and preventing readmission.

A large-scale retrospective analysis involving Atrium Health provided powerful evidence of EndoTool’s impact on reducing severe hypoglycemia with only 15 episodes in a year ⁸. Atrium Health conducted smaller-scale studies that demonstrated decreased length of stay, cost savings, and reduced time to control.

The Outpatient Edge: Continuous Diabetes Data in Glooko Useful for Heart Protection

While EndoTool focuses on acute inpatient stabilization, Glooko provides the essential, continuous digital health platform required for effective long-term diabetes management.

Glooko’s strength lies in its agnostic device compatibility with more than 200 diabetes and health monitoring devices and apps creating a unified view of the patient’s health far beyond just glucose readings. This holistic data aggregation allows monitoring diabetes data for cardiac risk factors such as:

• Agnostic Integration of Biometric Data: Glooko seamlessly integrates readings from various connected health monitoring devices, including blood pressure (BP) monitors and smart scales. By tracking BP and weight trends over time, the platform provides clinicians with blood pressure and weight data — two primary, modifiable risk factors for cardiovascular disease. When this health data is integrated into the EHR and viewable alongside other patient data, clinicians can monitor these factors for cardiovascular disease.
• Nutrition and Lifestyle Management: The platform supports patient-entered nutrition logs and activity data. Clinicians can use this detailed lifestyle information to provide precise, personalized counseling on diet and exercise, directly supporting the lifestyle management required to reduce cardiac-related risks, such as hyperlipidemia and insulin resistance.

Risk Stratification: Using Glucose Data to Support Vascular Protection

Sustained poor glycemic control is the primary driver of both microvascular and macrovascular complications⁷. Glooko uses comprehensive, aggregated glycemic data to empower risk monitoring and population management:

• Identifying High-Risk Glycemic Patterns: The platform utilizes advanced pattern recognition algorithms to identify consistent trends in high glucose variability and poor Time in Range (TIR). These metrics are essential for assessing a patient’s overall risk for micro- and macrovascular complications.
• CGM Risk Stratification and Focused Care: For clinics managing large populations, Glooko’s data visualization allows for CGM risk stratification. By quickly identifying patient cohorts with persistently low TIR or high glycemic variability (GV), healthcare providers can efficiently focus their clinical resources and outreach efforts on the specific populations who are at the highest immediate risk of adverse cardiovascular outcomes.

Final Word: A Unified Approach to Preventing Complications

In observance of February’s American Heart Month, the capabilities of EndoTool and Glooko support effective glucose management, which is recognized as an important element of diabetes care and overall cardiovascular health.

EndoTool’s core strength is its 11-factor algorithm and EREI calculation for safe, precise, and effective inpatient glycemic control, which is vital for accelerating care transitions and improving long-term health. Glooko’s comprehensive digital outpatient tools, including pattern recognition in the Glooko Patient Summary and lifestyle data integration, provide actionable data for clinicians, empowering patients to maintain glycemic targets, and potentially prevent macrovascular and microvascular risk factors complications.

Together, these technologies support a continuous, data-driven approach to diabetes care, which can contribute to an important element of overall cardiovascular health and further the mission of heart health.

References

1. American Diabetes Association. (2024). Standards of care in diabetes—2024. Diabetes Care, 47 (Supplement 1). https://diabetesjournals.org/care/issue/48/supplement_1
2. American Heart Association. (n.d.). Diabetes significantly increases risk of heart attack, stroke. DeTar Healthcare System. Retrieved February 2, 2026, from https://www.detar.com/news-room/diabetes-significantly-increases-risk-of-heart-att-21990
3. Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Green, L. A., Konstam, M. A., Lorenzi, F., Materson, J. R., Mitchell, M. E., Smith, S. C., Jr., Pasternak, R. C., Reusch, J. E., Sacco, R. S., Smith, E. H., Vitek, M. E., & Zheng, D. (2010). Cardiovascular disease and diabetes: An update. Circulation, 122(3), e320–e334. https://pmc.ncbi.nlm.nih.gov/articles/PMC3028955/
4. Cochran, S., Miller, E., Dunn, K., Burgess, W., Miles, W., & Lobdell, K. (2006). EndoTool software for tight glucose control for critically ill patients. Critical Care Medicine, 34(12), A68.
5. Grundy, S. M. (2019). Obesity, cardiovascular disease, and the American Heart Association. Journal of the American Heart Association, 8(12), e011295. https://www.ahajournals.org/doi/10.1161/JAHA.118.011295
6. Institute of Critical Care Medicine. (n.d.). [Specific guideline title related to glycemic control in critical care]. Retrieved February 2, 2026, from https://www.youtube.com/watch?v=aNpMzL1FLmU
7. Laakso, M., & Lehto, S. (2014). Contributors to mortality in high-risk diabetic patients. Diabetes Care, 37(10), 2798–2804. https://diabetesjournals.org/care/article/37/10/2798/30903/Contributors-to-Mortality-in-High-Risk-Diabetic
8. Price, C., & Aloi, J. (2024). Achieving Optimal Glucose Control in Critical Care Units at Atrium Health [Poster presentation]. American Diabetes Association 84th Scientific Sessions.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool’s ability to use available patient information within the hospital’s electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.

EHR integrations provide a single, holistic view of patient data to streamline clinical workflows and enable more informed, data-driven decision-making at the point of care for healthcare providers.

Rady Children’s Hospital Diabetes Program Director Carla Demeterco-Berggren, MD, PhD, and Michigan Medicine Project Manager Chris Dallas share how they leverage EHR-integrated diabetes workflows in the Glooko diabetes management platform to reduce manual burden, improve visibility, and scale team-based care.

Moderated by Glooko Senior Clinical Transformation Director Trisha Martinez, BSN, MBA, RN, the session also covers why bringing diabetes data directly into the EHR is critical for improving efficiency, coordination, and care delivery across health systems.

Key Takeaways

• Manual workflows eliminated: EHR integration replaces printing, scanning, copy/paste, and manual flowsheet entry with automated data delivery directly into the EHR.
• Significant time efficiency gains: Both Rady Children’s and Michigan Medicine reported meaningful reductions in documentation and intake time after integrating Glooko into their EHR workflows.
• Scalable, standardized care: One-click access, discrete flowsheet data, and remote visibility support telehealth expansion, improve coordination, and increase clinic capacity.

Watch the Webinar

Ready to bring diabetes patient data into the EHR?

Contact Team Glooko to discover how our seamless integrations with leading EHR systems, including Epic, Oracle Health, MEDITECH, Greenway Health, eClinicalWorks, NextGen, and Athenahealth, can transform your practice. By embedding our diabetes management platform directly within existing clinical workflows, we provide secure access to critical data while eliminating the inefficiency of switching between platforms.

MKT-0522 01

The diabetes industry won’t just evolve in 2026. It will continue to undergo a fundamental shift in how care is defined, delivered, and experienced. What was once a landscape dominated by manual tracking and reactive treatments has transformed into a proactive, connected, data-driven ecosystem of diabetes devices, management platforms, manufacturers, digital therapeutics, consumables, educators, and drug therapies.

In 2026, the focus is no longer just about managing diabetes, but about mastering it through integrated data, connected devices and apps, and AI-enabled insights. Glooko’s core mission has always been to bridge the gap between people living with diabetes and healthcare providers through clear, actionable data. This year, we are strengthening that connection by offering innovative solutions like EndoTool, developed by Monarch Medical Technologies, a Glooko Company, and Glooko. Together, these technologies can bridge the continuum of care from inpatient glycemic management to outpatient diabetes management.

To better understand where the industry is going, we asked our experts for their insights and predictions for 2026.

Advancing Diabetes and Glycemic Management in 2026

“The diabetes landscape is set for a massive transformation in 2026. With the launch of the CMS ACCESS Model, we are shifting from simply tracking data to rewarding positive health outcomes during hospital stays. However, as a wave of new CGMs, AI-enabled health software and wearables, and smart pens hits the market, these technologies can quickly overwhelm outpatient care teams. Trusted digital health solutions that bridge these settings, unifying disparate devices into one clear, actionable clinical picture using data, will be key.

This move toward data liquidity means vital information is no longer trapped in a single device or clinical encounter. By integrating inpatient systems with outpatient platforms, care can be more proactive and continuous, especially as new federal quality measures for glycemic safety take full effect this year. We aren’t just looking at numbers anymore; we need to use intelligent, AI-powered insights to make the daily burden of diabetes feel lighter. We’re moving beyond ‘tech for tech’s sake’ and toward a simpler, more connected reality that puts the person before the data.”

– Mike Alvarez, CEO, Glooko

The Rise of New Digital Health Standards and Connected Care

“In 2026, the strategic focus for health systems will shift from fragmented point solutions to a unified continuum of care. As hospitals face tightening margins and new outcome-based payment models like CMS ACCESS, they’ll seek integrated platforms that standardize management for chronic conditions like diabetes across both inpatient and outpatient settings. By consolidating disparate tools into a single, EHR-integrated ecosystem, systems can reduce the cost of maintaining multiple interfaces.

Remote patient monitoring will also see new life in 2026. New programs like the federal Rural Health Transformation Program are bridging the „digital divide” and refocusing on the benefits of connected, digital-forward care. This $50 billion funding allows underserved, rural clinics to adopt advanced AI and remote monitoring tools that were previously limited to urban centers, enabling evidence-based chronic condition management closer to home. By leveraging grants to modernize interoperability and cybersecurity, rural healthcare providers ensure that high-quality, connected diabetes care is no longer determined by a patient’s zip code, but is instead the universal standard.”

– Rich Glenn, President, Connected Care, Glooko

Evolving from Siloed Data Collection to Integrations and Precision Engagement

“This year, we will keep expanding our current support of episodic care to include continuous care, evolving beyond our expertise in data collection to the design of digital ecosystems that bridge the gap between people with diabetes, their device data, and healthcare providers. This shift will replace fragmented data silos with a unified infrastructure where information from diabetes devices and health monitoring apps flow seamlessly into clinicians‘ primary workflows via EHR integrations. We must ensure that continuous data isn’t an overwhelming burden, but an enabling and actionable asset. This collaborative framework alleviates burnout by giving the entire care team an on-demand ‘single source of truth,’ allowing care teams to intervene proactively and spend less time navigating software and more time practicing at the tops of their licenses.

Given recent FDA guidance on wellness wearables and clinical decision support software, we may now be entering a new era of precision engagement fueled by AI. With the latest generations of CGM devices and automated insulin delivery (AID) systems, the field has already moved beyond just seeing data to predicting outcomes and using AI to forecast hypoglycemic events with immediate, context-rich alerts to the person with diabetes. This automation allows patients to manage their care more independently than ever before. However, people with diabetes still benefit from expert teams that can co-pilot their care. There will always be a vital need for care teams to step in when clinical complexity arises or the individual is not achieving their diabetes management goals.”

– Mark Clements, MD, PhD, Chief Medical and Strategy Officer, Glooko

Making Glycemic Safety a Mandatory Protocol

“In 2026, inpatient glycemic safety will transition from a clinical preference to a mandatory system requirement. With CMS now linking reimbursement and quality ratings to the reporting of severe glycemic events, hospitals can no longer rely on the manual vigilance of individual clinicians to manage insulin therapy. Success now requires moving away from fragmented „sliding scale“ protocols and toward purpose-built platforms like EndoTool that ensure consistent, evidence-based dosing and the ability to track outcomes in real time. By treating glycemic management as core safety infrastructure, hospitals and health systems can reduce costly variability, meet new regulatory demands, and allow clinicians to focus on patient care rather than manual calculations.”

– Paul Chidester, MD, Medical Director, Glooko

View Dr. Chidester’s full 2026 outlook on glycemic safety

Solving Specialist Shortages and Clinician Burnout Through Integrated AI and Enhanced Patient Literacy

“Clinician burnout will remain a top priority in 2026, driven in part by the mental exhaustion of managing disjointed tools outside the EHR. This year marks a turning point: embedding integrated data and interoperability within existing workflows will automate administrative tasks, streamline documentation, and provide unified patient views for better clinical decisions. The result will likely be improved provider capacity, proactive care delivery, and sustainable models that optimize both clinical and operational outcomes.

As the endocrinologist shortage intensifies, primary care teams will increasingly leverage specialized healthcare AI tools, including ChatGPT for Healthcare, to reduce administrative burden and enable top-of-scope care delivery, effectively increasing capacity without adding staff.

We will continue to be immersed in the era of the AI-empowered patient. Patients already use tools like ChatGPT Health to synthesize their data, including glucose trends and lab results, before appointments. This increasing health literacy will continue to transform basic data reviews into high-value, collaborative discussions where both clinicians and patients leverage AI for more informed decision-making.”

– Trisha Martinez, BSN, MBA, RN, Senior Director, Clinical Transformation, Glooko

Securing the Digital Health Ecosystem to Thwart AI-Driven Cyberattacks

“In 2026, healthcare data privacy and cybersecurity will undergo a fundamental shift as cyber threats transition to AI-driven, autonomous models. Healthcare organizations must pivot toward ‘agentic resilience,’ a proactive approach leveraging agentic AI, autonomous systems capable of making decisions and executing tasks. These agents can address the vulnerabilities inherent in connected medical ecosystems, such as the possible cyberattack risks present in clinical workflows and medical devices, including connected insulin pumps and CGMs.

To mitigate security risks in 2026, healthcare organizations should also transition toward a robust security framework that replaces traditional passwords with identity-based access control and advanced authentication methods, such as biometric passkeys and MFA. By implementing universal verification, every access request can be rigorously validated regardless of its source, ensuring the integrity of clinical workflows and protecting sensitive health data from unauthorized entry.”

– Ben Chang, Vice President, Security and IT Operations, Glooko

Entering a Highly-Competitive, Integration-First Diabetes Device Ecosystem

“We’re entering the year in a global diabetes landscape that has matured into a competitive, integration-first ecosystem that demands collaboration. With the global diabetes device market projected to exceed $37.9 billion, we are seeing an influx of regional manufacturers offering new device alternatives, giving healthcare providers and people with diabetes a wider array of care choices. This diversification is further accelerated by the mainstream adoption of tubeless patch pumps, CGMs, and non-invasive wearable technologies tailored for the Type 2 diabetes and wellness segments.

From a partnership perspective, these trends reinforce a vital market truth that hardware is no longer a standalone solution. As the number of devices expands, the ultimate competitive advantage belongs to those who prioritize interoperability, integrating effortlessly into the patient’s life and the clinician’s EHR system.”

– Dave Conn, Executive Vice President, Global Alliances, Glooko

Furthering Connected Diabetes Care in Europe

„We’ll continue to move away from disconnected diabetes devices and toward integrated digital ecosystems. As connected care becomes the standard for delivering value, diabetes management will increasingly rely on a coordinated combination of medication, smart hardware, and artificial intelligence, all operating under the supervision of healthcare professionals through structured remote monitoring.

For remote monitoring to be effectively adopted, it must be embedded within national and regulatory frameworks defined by local health authorities. Strict alignment with evolving EU regulations on AI and health data will also remain a central priority.

In terms of devices, the evolution of algorithm-driven AID systems into sophisticated ‘digital companions’ will be the catalyst for a broader diabetes management transformation. By combining predictive AI with remote monitoring, healthcare providers can anticipate patient needs and manage populations remotely, offering a scalable solution to Europe’s workforce challenges by effectively shifting care from hospital settings into the home.“

– Alex Evans, Vice President, Connected Care, EMEA, Glooko

Smarter Technology to Empower People Living with Diabetes

„Over the past few years, managing my diabetes finally felt less like a full-time job and more like a background app running on my phone. We’ve moved away from the constant stress of finger sticks and manual math thanks to the latest AID systems and high-tech sensors that talk to each other better than ever before. These smart systems do the heavy lifting for many, catching highs and lows before they even happen, which takes a huge weight off the shoulders of people with diabetes. Even for those of us who don’t use a pump, connected smart pens can now automatically log every dose, so there’s a lot less guessing and worrying. In 2026, I think we’ll see even more technology that helps further reduce burnout, keep costs more manageable, and maintain time in range — all while letting people think about diabetes a little less.”

– Hadley Horton, Senior Partner Manager, Glooko

Ready to prepare your hospital, health system, or clinic for the rest of 2026?

Contact our team for a demo of our outpatient Glooko diabetes management platform and inpatient EndoTool Glucose Management System.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.

In clinics and hospitals across Europe, healthcare providers are facing the common challenge of administrative overload.

We’ve heard that care teams at clinics and hospitals in the United Kingdom, Germany, Austria, Switzerland, Norway, Sweden, and Denmark need a more streamlined way to securely access our diabetes management platform and a more seamless integration of health data of patients into their daily clinical workflows.

Designed to streamline diabetes care workflows, our latest enhancements, including SSO and EHR integration, aim to provide secure access, automate workflows, and save care teams time.

Simplified and Secure Access with Single Sign-On

In fast-paced clinical environments, every second counts. Between patient consultations and appointment follow-ups, the last thing healthcare professionals need is another set of login credentials to memorize.

To increase efficiency, the Glooko diabetes management platform, compliant with GDPR and the NHS Data Security & Protection Toolkit, features single sign-on (SSO) functionality. Instead of using a separate username and password, clinical teams can access Glooko using their existing hospital credentials.

Why are clinics switching to SSO in Europe?

• Seamless Access: The experience is intuitive. Users simply enter their professional email address and Glooko automatically authenticates them against their healthcare organization’s existing identity management platform.
• Enhanced Security: By leveraging a hospital’s existing security protocols, SSO reduces the risks associated with weak or recycled passwords, keeping sensitive patient health data secure.
• Maximum Efficiency: No more time wasted on login screens, forgotten password requests, and locked accounts.
• Fast Implementation: The setup process is straightforward and we can typically have healthcare organizations connected to our platform, backed by leading security certifications, in less than two days.

End Manual Data Entry and Stop Toggling with EHR Interoperability

The administrative burden of maintaining patient records is one of the primary causes of clinician burnout. Too often, healthcare providers are forced to act as data entry clerks, manually transcribing glucose logs, insulin data, and reports into the EHR (electronic health record), instead of analyzing that data to improve care.

To eliminate this manual work and limit switching between screens, Glooko offers integrations designed to automate the flow of health information, making the EHR and our diabetes management platform work as a unified system.

By bridging the gap between systems, Glooko helps reduce manual burden and combat clinician burnout:

• Launch from EHR: Open a patient’s full Glooko profile directly from the EHR interface. No extra tabs, no re-searching for names.
• Sync to EHR: Automatically upload diabetes data and detailed reports from Glooko straight into the EHR to keep more comprehensive patient records.

By connecting these two systems, care teams can spend less time managing software and more time with their patients.

Ready to simplify your clinic’s digital environment?

Contact Team Glooko to find out the next steps needed to activate SSO and integrate our innovative diabetes management solution into the EHR.

For technical details, visit our API and EHR Integration Portal.

We’re excited to share the latest updates included in Glooko Web 25.4 and Glooko Mobile 6.14, which are designed to help healthcare providers and care teams move faster with easier-to-understand risk insights, while also making it easier for people living with diabetes to connect devices and apps and remotely share data with their care teams.

Enhancements to the Glooko Clinic Dashboard

The Glooko clinic dashboard, designed to improve diabetes population health management and available in select countries, now features enhanced usability and accuracy improvements, making risk insights clearer for faster action across clinics, hospitals, and health systems.

Other enhancements to our population health tool include:

• Clearer risk visibility: An updated Time in Range layout makes low and very low glucose risk easier to identify at a glance.
• Smarter patient ranking: Patients with diabetes are prioritized by risk category, then by severity of the triggering metric.
• More precise metrics: Risk indicators are displayed with greater precision for clearer comparison and trend tracking.

More Efficient Patient Review in the Glooko Web App

The patient list in the Glooko Web App for healthcare providers has been enhanced to support faster, more efficient workflows and smoother navigation.

Care teams can now see more patient data at once with a wider default view that reduces horizontal scrolling, sort patients better with improved cues that make patient order easier to understand, and see key context through a revised header that stays visible as they scroll through the list.

Streamlined Clinical Workflows with Full Glooko Access in Epic

Healthcare providers using Patient Portal for Professionals can now access the full Glooko Web App directly within the Epic EHR system using SSO via SMaRT on FHIR, reducing platform switching and streamlining daily workflows.

Some of the benefits of this helpful enhancement include launching our diabetes management platform without leaving the EHR or logging in again, the use of core features including the clinic dashboard, patient list, and device assignment within Epic, faster review and action using key patient diabetes data, and reduced clinician burnout from not context switching.

If your clinic is interested in this feature, please email [email protected].

Simplified Device and App Management for People with Diabetes

Managing diabetes and health monitoring devices and apps is now quicker and intuitive in the Glooko Mobile App.

Our newly enhanced search and smarter filtering, better device categorization, and refreshed visuals, including logos, make it easier for people with diabetes to find and connect their devices and apps with fewer clicks. The update also features shortcuts to speed up Glooko’s seamless integration with more than 200 compatible diabetes and health monitoring devices and apps. Once connected, patient data can be securely shared remotely with care teams who can make more informed treatment decisions.

More Information on the Latest Glooko Release

To learn more about these updates, check out the full release notes on our Support Center or reach out to your dedicated Glooko Customer Success Manager.

Every year, the American Diabetes Association (ADA) updates its Standards of Care in Diabetes, the clinical foundation that guides how we screen, diagnose, manage, and support people living with diabetes. The 2026 guidelines are among the most comprehensive to date, with a clear message: diabetes care must evolve to meet rising complexity, widening gaps in care, and the growing urgency to improve outcomes across entire populations.

This year’s recommendations underscore that our work in connected care has never been more important.

Population health requires stronger systems, better data, and integrated teams

The Standards highlight that population health is not simply a measurement framework, but rather a commitment to improving outcomes for groups of people who experience very different barriers, risks, and trajectories. The ADA emphasizes team-based, patient-specific care, timely treatment decisions, reliable data metrics to track quality, and a culture of continuous improvement across health systems.

These priorities mirror what clinicians experience every day: fragmented systems, variable follow-up, and the challenge of navigating high-risk patients without the right tools or insights. Platforms like Glooko, which provide timely insights, structured data access, clinical integration directly into the EHR, and simplified workflows, play a direct role in enabling the proactive care models the ADA calls for. When healthcare professionals manage a large population of patients with diabetes, they often lack a clear, organized, and comprehensive view of patients’ pertinent health data.

To help address this challenge, we designed the new clinic dashboard in the Glooko diabetes management platform. This is critical in providing insights into metabolic factors and indications of clinical risk to facilitate shared decision making conversations in a personalized way, with patients and their support systems.This patient-centric approach helps healthcare providers–including primary care providers, endocrinologists, and nurses, at hospitals, health systems, and clinics–provide individualized care recommendations that are patient-specific.

The Population Metrics section of the new Glooko clinic dashboard helps care teams understand the overall health and engagement of their clinic’s patient population in a centralized and concise view. By centralizing population-level metrics, care teams can more quickly identify disengaged patients, prioritize outreach, and intervene earlier, supporting both quality goals and clinic efficiency.

Glycemic management is becoming more nuanced and more actionable

The 2026 Standards reinforce the importance of individualized glycemic assessment. A1C remains central, but ADA again stresses the clinical value of time in range (TIR), time below range (TBR), and continuous glucose monitoring (CGM) metrics for real-time, person-centered care. We observed similar trends in our 2025 Annual Diabetes Report.

For many clinicians, the challenge is not whether to use CGMs, it’s how to interpret data efficiently and translate trends into action. This is where connected, device-agnostic platforms are essential. Having glucose data delivered in clinically meaningful formats, integrated with insulin dosing, meals, and activity, allows teams to identify risks earlier, adjust therapy faster, and support patients between visits.

This is especially critical for populations highlighted in the Standards: individuals facing food or housing insecurity, young adults with rising complication rates, rural communities with limited access, and older adults with shifting needs. Digital tools do not replace clinicians; they expand their reach.

Inpatient glycemic safety: Operationalizing the ADA’s call for safer insulin use

The 2026 Standards dedicate significant space to preventing hypoglycemia, hyperglycemia, and hyperglycemic crises, events that disproportionately impact people with diabetes during hospitalization or acute illness. ADA guidance reinforces the need for:

• Structured insulin protocols
• Frequent monitoring to adjust dosing
• Systems that minimize variation in clinical decision-making
• Approaches that reduce risk during periods of physiologic instability

This is exactly where EndoTool, developed by Monarch Medical Technologies, a Glooko Company, plays a transformative role. EndoTool brings advanced, patient-specific insulin dosing to inpatient settings, enabling dynamic adjustments based on each patient’s evolving physiology. By reducing glycemic variability and supporting timely identification of trends, EndoTool aligns directly with ADA recommendations around individualized glycemic targets, hypoglycemia prevention, and safer transitions of care.

As health systems work to connect inpatient and outpatient data streams, as the Standards increasingly encourage, EndoTool and Glooko have the potential to create a more actionable ecosystem. Patients leave the hospital with a more stable glycemic trajectory, and outpatient teams gain a clearer picture of what occurred during admission, supporting smoother recovery and reduced readmissions.

A vision aligned with where diabetes care is going

Across all 2026 recommendations, a single theme stands out: better outcomes depend on proactive, connected, team-based, data-driven care. The Standards call for more timely therapy changes, broader Diabetes Self-Management Education and Support (DSMES) access, stronger telehealth offerings, and improved system-level accountability.

At Glooko, we’re proud to support clinicians and health systems in delivering on those goals by making diabetes data easier to use, helping teams coordinate more effectively, and empowering people with diabetes with insights that fit their daily lives.

The work ahead is significant, but the path is clearer than ever. Together, we can turn these standards into sustained, measurable improvements in the health of patients and the clinician experience.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.